NCT06091956View on ClinicalTrials.gov

A Study of Deucravacitinib to Treat LPP and FFA

PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

May 21, 2024

Study Completion Date

December 24, 2024

Conditions

Lichen Planopilaris

Interventions

DRUG

Deucravacitinib

6 milligram (mg) orally administrated, twice daily

Trial Locations (2)

32224

Mayo Clinic Florida, Jacksonville

85259

Mayo Clinic Arizona, Scottsdale

Sponsors

Lead Sponsor

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Mayo Clinic

OTHER

NCT06091956 - A Study of Deucravacitinib to Treat LPP and FFA | Biotech Hunter | Biotech Hunter